Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Esperion Theraptc (ESPR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,167,307
  • Shares Outstanding, K 26,811
  • Annual Sales, $ 0 K
  • Annual Income, $ -166,990 K
  • 36-Month Beta 2.14
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -1.33
  • Number of Estimates 6
  • High Estimate -1.05
  • Low Estimate -1.49
  • Prior Year -1.44
  • Growth Rate Est. (year over year) +7.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.95 +6.62%
on 01/22/19
49.35 -11.53%
on 02/05/19
+0.61 (+1.42%)
since 01/18/19
3-Month
38.08 +14.65%
on 12/24/18
58.50 -25.37%
on 12/04/18
-2.03 (-4.44%)
since 11/20/18
52-Week
33.06 +32.06%
on 05/03/18
82.68 -47.19%
on 02/27/18
-32.13 (-42.39%)
since 02/20/18

Most Recent Stories

More News
Constellation Pharmaceuticals Announces Appointment to Board of Directors

Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Scott...

ESPR : 43.71 (+0.39%)
CNST : 10.55 (-2.41%)
Update in Lawsuit for Investors in NASDAQ: ESPR shares against Esperion Therapeutics, Inc. announced by Shareholders Foundation

The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR).

ESPR : 43.71 (+0.39%)
Watch for Esperion Therape to Potentially Rebound After Falling 4.62% Yesterday

Esperion Therape (NASDAQ:ESPR) traded in a range yesterday that spanned from a low of $41.06 to a high of $41.35. Yesterday, the shares fell 4.6%, which took the trading range below the 3-day low of...

ESPR : 43.71 (+0.39%)
Shares of La Jolla Pharm Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (LJPC , DVAX , ESPR , SGMO , PTLA )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

ESPR : 43.71 (+0.39%)
LJPC : 5.84 (-3.15%)
DVAX : 10.99 (+0.18%)
Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination Tablet

MUNICH, January 7, 2019 /PRNewswire/ --

ESPR : 43.71 (+0.39%)
Esperion Announces Agreement with Daiichi Sankyo Europe (DSE) to Commercialize Bempedoic Acid in Europe

- Esperion to Receive $300 Million in Upfront and Near-term Milestones -

ESPR : 43.71 (+0.39%)
Esperion to Present at the 37th Annual J.P. Morgan Healthcare Conference

Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated...

ESPR : 43.71 (+0.39%)
JPM : 105.36 (+0.17%)
Stemline Therape is Among the Companies in the Biotechnology Industry with the Best Relative Performance (STML , ATRA , ESPR , ADMS , HRTX )

Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming....

ESPR : 43.71 (+0.39%)
STML : 11.50 (-0.43%)
ATRA : 39.31 (-2.38%)
Do Options Traders Know Something About Esperion (ESPR) Stock We Don't?

Investors need to pay close attention to Esperion (ESPR) stock based on the movements in the options market lately.

ESPR : 43.71 (+0.39%)
Esperion Announces Late-Breaking Oral Presentation of Final Study 3 Results (1002-046) of Bempedoic Acid at the American Heart Association Scientific Sessions 2018

Esperion (NASDAQ:ESPR), today announced that the final Phase 3 results from Study 3 (1002-046, also known as CLEAR Serenity) were presented at the American Heart Association (AHA) Scientific Sessions in...

ESPR : 43.71 (+0.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade ESPR with:

Business Summary

Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan.

See More

Key Turning Points

2nd Resistance Point 46.66
1st Resistance Point 45.10
Last Price 43.71
1st Support Level 42.42
2nd Support Level 41.30

See More

52-Week High 82.68
Fibonacci 61.8% 63.73
Fibonacci 50% 57.87
Fibonacci 38.2% 52.01
Last Price 43.71
52-Week Low 33.06

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar